Literature DB >> 31073442

Catheter-Associated Blood Stream Infections in Intracardiac Lines.

Xiomara Garcia1, Sherry Pye2, Xinyu Tang3, Jeffrey Gossett3, Parthak Prodhan1, Adnan Bhutta4.   

Abstract

Purpose  Right atrial (RA) or intracardiac lines are commonly used for hemodynamic monitoring in children undergoing cardiac surgery. In some institutions, these lines are used as the preferred long-term access line due to concerns for catheter-associated blood stream infections (CABSI) and catheter-related venous thrombosis with central lines in other locations. However, the rates and risk factors for CABSI and other complications are not known for RA lines. We undertook this study to estimate CABSI rates for RA lines in comparison with central catheters of various types and locations and to evaluate the incidence of other complications associated with the use of RA lines. Methods  After approval from the Institutional Review Board, a retrospective review of all patients undergoing cardiac surgery at Arkansas Children's Hospital between the dates of January 1, 2006 and December 31, 2011 was performed. Demographic data, clinical features, and outcomes were summarized on a per-patient level. Type, location of placement, and duration of all centrally placed catheters as well as associated complications were recorded. Central venous lines (CVL) used in our unit include peripherally inserted central catheters (PICC) lines, and antibiotic and heparin coated double or triple lumen lines placed in internal jugular (IJ), femoral (Fem), or RA positions. The data were analyzed using statistical software STATA/MP. Results  A total of 2,736 central lines were used in 1,537 patients. Data on line duration, alteplase use, and percentage of lines developing CABSI are described in the study. Disease severity as assessed by risk-adjusted classification for congenital heart surgery (RACHS) score ( p  < 0.046), year of placement ( p  < 0.001), and line type adjusted for thrombolytic (alteplase) use are significantly associated with risk of any CABSI. Overall, IJ and RA lines had least risk of CABSI while PICC lines had the highest CABSI rates. RA lines are also associated with other medically significant complications. Conclusion  The CABSI rates associated with RA lines are lower than those seen with PICC lines. However, RA line use is associated with other, potentially significant complications. RA lines may be used cautiously as long-term access lines in cardiac patients in whom it is important to preserve venous patency for future interventions.

Entities:  

Keywords:  alteplase; catheter-associated blood stream infections; intracardiac lines; peripherally inserted central catheters; right atrial lines; risk-adjusted classification for congenital heart surgery

Year:  2016        PMID: 31073442      PMCID: PMC6260298          DOI: 10.1055/s-0036-1596064

Source DB:  PubMed          Journal:  J Pediatr Intensive Care        ISSN: 2146-4626


  11 in total

1.  Reduction of bloodstream infections associated with catheters in paediatric intensive care unit: stepwise approach.

Authors:  Adnan Bhutta; Craig Gilliam; Michele Honeycutt; Stephen Schexnayder; Jerril Green; Michele Moss; K J S Anand
Journal:  BMJ       Date:  2007-02-17

Review 2.  Cardiac tamponade after removal of atrial intracardiac monitoring catheters in a pediatric patient: case report.

Authors:  L J Johnston; D F McKinley
Journal:  Heart Lung       Date:  2000 Jul-Aug       Impact factor: 2.210

Review 3.  Thrombolytic therapy for central venous catheter occlusion.

Authors:  Jacquelyn L Baskin; Ulrike Reiss; Judith A Wilimas; Monika L Metzger; Raul C Ribeiro; Ching-Hon Pui; Scott C Howard
Journal:  Haematologica       Date:  2011-12-16       Impact factor: 9.941

4.  Risk factors for central line-associated bloodstream infection in pediatric intensive care units.

Authors:  Matthew C Wylie; Dionne A Graham; Gail Potter-Bynoe; Monica E Kleinman; Adrienne G Randolph; John M Costello; Thomas J Sandora
Journal:  Infect Control Hosp Epidemiol       Date:  2010-10       Impact factor: 3.254

Review 5.  Consensus-based method for risk adjustment for surgery for congenital heart disease.

Authors:  Kathy J Jenkins; Kimberlee Gauvreau; Jane W Newburger; Thomas L Spray; James H Moller; Lisa I Iezzoni
Journal:  J Thorac Cardiovasc Surg       Date:  2002-01       Impact factor: 5.209

6.  Transthoracic intracardiac catheters in pediatric patients recovering from congenital heart defect surgery: associated complications and outcomes.

Authors:  H R Flori; L D Johnson; F L Hanley; J R Fineman
Journal:  Crit Care Med       Date:  2000-08       Impact factor: 7.598

Review 7.  Central venous catheter tip in the right atrium: a risk factor for neonatal cardiac tamponade.

Authors:  J C Darling; S J Newell; O Mohamdee; O Uzun; C J Cullinane; P R Dear
Journal:  J Perinatol       Date:  2001 Oct-Nov       Impact factor: 2.521

Review 8.  Management of occlusion and thrombosis associated with long-term indwelling central venous catheters.

Authors:  Jacquelyn L Baskin; Ching-Hon Pui; Ulrike Reiss; Judith A Wilimas; Monika L Metzger; Raul C Ribeiro; Scott C Howard
Journal:  Lancet       Date:  2009-07-11       Impact factor: 79.321

9.  Alteplase use for malfunctioning central venous catheters correlates with catheter-associated bloodstream infections.

Authors:  Courtney M Rowan; Kathryn E Miller; Andrew L Beardsley; Sheikh S Ahmed; Luis A Rojas; Terri L Hedlund; Richard H Speicher; Mara E Nitu
Journal:  Pediatr Crit Care Med       Date:  2013-03       Impact factor: 3.624

10.  Upper body central venous catheters in pediatric cardiac surgery.

Authors:  Jeffrey W Miller; Dien N Vu; Paul J Chai; Janet H Kreutzer; J Blaine John; David F Vener; Jeffrey P Jacobs
Journal:  Paediatr Anaesth       Date:  2013-09-19       Impact factor: 2.556

View more
  1 in total

1.  Right Atrial Lines as Primary Access for Postoperative Pediatric Cardiac Patients.

Authors:  Pilar Anton-Martin; Nina Zook; Justin Kochanski; Meredith Ray; John J Nigro; Shilpa Vellore
Journal:  Pediatr Cardiol       Date:  2022-09-12       Impact factor: 1.838

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.